Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asenapine Long-Term Extension in Schizophrenia
NCT00156065Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Sep 2005
- Primary completion
- Sep 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of asenapine in schizophrenia (2 arms), sponsored by Organon & Co. Primary endpoints: Loss of Effect Over Time at 52 weeks and Median Survival Time of Effect at 52 weeks. Started Sep 2005; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00156065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00156065.